The research interests of Manoj K. Jain, M.D., focus on molecular imaging with positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) imaging that uses radiolabeled molecules as probes to visualize, characterize and quantify disease processes at the cellular level. Dr. Jain is also involved in research related to theranostics, a targeted therapy based on specific diagnostic tests to treat tumors and metastatic disease.
- Nuclear medicine in neurology. Dr. Jain's research involves PET-CT and PET-MRI using radioactive molecules (F-18 FDG, F-18 Amyvid, C-11 PIB, F-18 Tau) for the better understanding of neurodegenerative diseases, neuroinflammation and parkinsonism.
- Theranostics diagnosis and therapy. Dr. Jain has participated in neuroendocrine tumor theranostics clinical trials and is now getting involved with prostate cancer Theranostics trials.
- Cardiac imaging. Dr. Jain is working with cardiologists on PET imaging of cardiac inflammation.
- Translational medicine. Dr. Jain has interest in the development of novel radiolabeled molecules for PET imaging from disease model to human. Translational PET imaging with novel radiolabeled molecules potentiates benchtop research into patient care.
Significance to patient care
Dr. Jain's molecular imaging research focuses on early noninvasive detection of disease processes, differentiation of neurological processes and administration of radiolabeled targeted therapy for personalized patient care. The use of radiolabeled molecules with PET or SPECT also allows noninvasive quantification of disease and early monitoring of response to therapy.